SCYNEXIS Inc names Zynerba Pharmaceuticals Inc CEO Armando Anido to its board
Zynerba sinks after total failure in phase 2 cannabidiol trial | Fierce Biotech
Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel; Street Sees 75% Upside
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
Zynerba: Repeated Trial Failures, Some Post Hoc Success (NASDAQ:ZYNE) | Seeking Alpha
Big medical bet: Why this Philly area pharma company's shares jumped 65 percent in a week
Zynerba Pharmaceuticals, Inc. General Corporate Statement (Form8) - Zynerba Pharmaceuticals (NASDAQ:ZYNE) - Benzinga
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™
Zynerba hopes to crack fragile X at last | Evaluate
Stan Banks - Director of CMC and Product Development - Zynerba Pharmaceuticals | LinkedIn
Zygel's anticipated impact on underserved fragile X syndrome market
g260361mmi021.gif
Zynerba Pharmaceuticals - Whether They've Cracked The Code For Fully Methylated FX Syndrome Patients (NASDAQ:ZYNE) | Seeking Alpha
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
FDA | PotNetwork
Should You Buy Zynerba Pharmaceuticals Inc (ZYNE) Stock on Thursday?
Zynerba Pharmaceuticals, Inc. General Corporate Statement (Form8) - Zynerba Pharmaceuticals (NASDAQ:ZYNE) - Benzinga
Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders
zynerba-pipeline-10-16 - Zynerba
Zynerba Pharmaceuticals Inc receives guidance from the US Food and Drug Administration on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome
